MALT lymphoma · 11 regimens
Cost vs Efficacy · 5 points
| Regimen | Biomarker | Cost/cycle ↓ | Cycle | PFS ↕ | OS ↕ | Est. cycles | Course cost ↕ | Evidence |
|---|---|---|---|---|---|---|---|---|
Lenalidomide and Rituximab (R2) Variant #08 | — | R 106 523 | 28d | ~39.4 mo | — | ~13 | ~R 141 371 PFS proxy · indirect | 5 |
Chlorambucil and Rituximab (RClb) Variant #01 | — | R 52 650 | 42d | — | — | 6 | R 160 474 PFS proxy | 1 |
Cladribine and Rituximab Variant #01 | — | R 48 077 | 21d | — | — | ~6 | ~R 288 462 indirect | — |
Cladribine monotherapy Variant #03 | — | R 34 921 | 35d | — | — | ~1 | ~R 34 921 indirect | — |
Fludarabine and Rituximab (FR) Variant #01 | — | R 34 157 | 28d | — | — | ~6 | ~R 204 943 indirect | — |
Bendamustine and Rituximab (BR) Variant #01 | — | R 33 874 | 28d | ~39.6 mo | — | ~7 | ~R 237 120 PFS proxy · indirect | 18 |
MCP Variant #01 | — | R 6 850 | 28d | — | — | ~8 | ~R 54 799 indirect | — |
Bortezomib monotherapy Variant #03 | — | R 6 762 | 21d | ~30.3 mo | — | ~8 | ~R 54 096 PFS proxy · indirect | 5 |
Chlorambucil monotherapy Variant #03 | — | R 2 355 | 28d | ~12.6 mo | ~69.7 mo | ~13 | ~R 30 610 PFS proxy · indirect | 6 |
Lenalidomide monotherapy Variant #01 | — | R 2 178 | 28d | ~30.8 mo | — | ~24 | ~R 52 272 PFS proxy · indirect | 2 |
Rituximab monotherapy Variant #09 Partial | — | — | 28d | ~20.3 mo | — | ~1 | — | 17 |
11 of 11 regimens shown